Daily Oral Paltusotine Maintains Acromegaly Treatment Benefit in Phase 3 Trial


Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

Daily Oral Paltusotine Maintains Acromegaly Treatment Benefit in Phase 3 Trial

Monica R. Gadelha, MD, PhD

A once-daily investigative oral drug was associated with a significant rate of patients with acromegaly maintaining insulin-like growth factor (IGF-1).

Paltusotine, an investigational compound from Crinetics Pharmaceuticals, achieved statistically significant improvements in primary and secondary efficacy endpoints in the phase 3 PATHFNDR-1 trial, a 36-week assessment with an open-label extension that is comparing the agent to placebo in patients with the rare excessive growth hormone (GH) disorder.

The findings implicate a potential pathway toward paltusotine becoming a first-of-its kind treatment regimen for patients with acromegaly—a severe, potentially deadly disease that significant impacts daily functioning and quality of life—by introducing a less invasive method of care to the market.

In a statement from Crinetics on Monday, investigators reported significant outcomes with paltusotine in the randomized, double-blind, placebo-controlled PATHFNDR-1 trial, 1 of 2 ongoing phase 3 assessments of the daily oral drug in patients with acromegaly switching from standard-care injection depot somatostatin analogs.

In this assessment, investigators were assessing the drug in patients who were biochemically controlled on octreotide or lanreotide depot monotherapy. They enrolled 58 adult patients with IFG-1 levels of ≤1.0 times the upper limit of normal (1.0x ULN) at baseline. Primary endpoint was proportion of patients maintaining the IFG-1 level after switching from octreotide or lanreotide depot monotherapy to paltusotine after 36 weeks of treatment.

Patients were randomized 1:1 to either treatment (n = 30) or placebo (n = 28) over the treatment period, then were invited to an optional open-label extension assessment of paltusotine in participants switching from somatostatin analogs.

According to the company, 25 (83%) patients receiving paltusotine achieved the primary endpoint of maintained IFG-1 levels <1.0x ULN after 36 weeks, versus only 1 (4%) of patients receiving placebo (P <.0001).

Investigators additionally observed significant achievement in the 3 key secondary endpoints of treatment, including:

  • Mean change from baseline IGF-1 level (0.04x ULN vs 0.83x ULN; P <.0001)
  • Mange change from baseline in Acromegaly Symptoms Diary Score (-0.6 vs 4.6; P = .02)
  • Proportion of patients who maintained GH levels of <1.0 ng/mL (20 [87%] vs 5 [18%]; P = .0003).

PATHFNDR-1 data additionally showed tolerability and no serious nor severe adverse events among participants treated with paltusotine; the most commonly reported treatment-emergent adverse events included arthralgia; headache; diarrhea; abdominal pain and nausea—each reported in fewer than 30% of treated patients.

While awaiting a fuller, peer-reviewed analysis of PATHFNDR-1 to be presented at upcoming scientific conferences, Crinetics executives and investigators expressed their excitement for the observed key outcomes.

“The results of PATHFNDR-1 are relevant to the patients we see every day in clinical practice who are biochemically controlled on standard-of-care injection,” Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the PATHFNDR program, said in a statement. “My colleagues and I are increasingly convinced many patients would appreciate an oral alternative which confers similar benefits without the burden and discomfort of the injections.”

Scott Struthers, PhD, founder and chief executive officer of Crinetics, stated that paltusotine was designed to become the preferred therapeutic option for patients with acromegaly. There’s hope it may become that soon enough.

“We could not be more excited by the results from PATHFNDR-1, which further reinforce our conviction that, if approved, paltusotine could address patients’ unmet need for a simple, oral, once-daily therapy,” Struthers said. “These data showed that upon switching from injected standard of care, paltusotine provided reliable, durable control of their disease. We intend to seek regulatory approval as quickly as possible once we complete the PATHFNDR-2 study early next year.”


Crinetics. Crinetics’ Once-Daily Oral Paltusotine Achieved The Primary And All Secondary Endpoints In The Phase 3 Pathfndr-1 Study Evaluating Treatment Of Patients With Acromegaly. Press release. Published September 10, 2023. https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/

Related Videos
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.